| Literature DB >> 27843660 |
Vera Vavinskaya1, Joel M Baumgartner2, Albert Ko3, Cheryl C Saenz4, Mark A Valasek1.
Abstract
Primary appendiceal mucinous lesions are uncommon and represent a spectrum from nonneoplastic mucous retention cysts to invasive adenocarcinoma. Low-grade appendiceal mucinous neoplasms (LAMNs) represent an intermediate category on this spectrum and can be classified according to whether or not they are confined to the appendix. Although LAMNs are frequently confined to the appendix, they can also spread to the peritoneum and clinically progress as pseudomyxoma peritonei (i.e., mucinous ascites). Thus, the appropriate classification of appendiceal primary neoplasia is essential for prognosis and influences clinical management. In addition, the precise classification, management, and clinical outcome of patients with disseminated peritoneal disease remain controversial. Here, we report an unusual case of LAMN with pseudomyxoma peritonei that initially presented with mucinous and bloody vaginal discharge. Pathological evaluation revealed low-grade appendiceal mucinous neoplasm with secondary involvement of the peritoneum, ovaries, and endometrial surface. Therefore, LAMN should be considered in the differential diagnosis of mucinous vaginal discharge.Entities:
Year: 2016 PMID: 27843660 PMCID: PMC5097800 DOI: 10.1155/2016/6841989
Source DB: PubMed Journal: Case Rep Obstet Gynecol ISSN: 2090-6692
Figure 1Peritoneal biopsies demonstrating involvement by low-grade appendiceal mucinous neoplasm (i.e., “low-grade mucinous carcinoma peritonei”); 20x, H&E, and scale bar = 100 micrometers.
Figure 2Diffuse reepithelialization of endometrium by low-grade appendiceal mucinous neoplasm with underlying weakly proliferative endometrium with focal hemorrhage; 4x, H&E, and scale bar = 500 micrometers.
Figure 3(a) High power view of the endometrium with the somewhat more eosinophilic neoplastic surface epithelium as compared to the underlying nonneoplastic endometrial glands; 20x, H&E, and scale bar = 100 micrometers. (b) Strong immunoreactivity for CK7 in both neoplastic surface epithelium and nonneoplastic endometrial glands; 20x and scale bar = 100 micrometers. (c) Strong immunoreactivity for CK20 in the neoplastic surface epithelium but not in nonneoplastic endometrial glands; 20x and scale bar = 100 micrometers. (d) Strong immunoreactivity for vimentin in nonneoplastic endometrial glands and stroma but not in neoplastic surface epithelium; 20x and scale bar = 100 micrometers. (e) Strong immunoreactivity for villin in the neoplastic surface epithelium but not in nonneoplastic endometrial glands; 20x and scale bar = 100 micrometers. (f) Strong immunoreactivity for Cdx-2 in the neoplastic surface epithelium but not in nonneoplastic endometrial glands; 20x and scale bar = 100 micrometers. (g) Strong immunoreactivity for Pax-8 in nonneoplastic endometrial glands but not in neoplastic surface epithelium; 20x and scale bar = 100 micrometers.